BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF CHRONIC PSYCHOTROPIC DRUG ADMINISTRATION

Authors

  • Sophie L. Harrington Department of Neuropharmacology and Behavioral Sciences London Biomedical Research Institute, United Kingdom

Keywords:

psychotropic drugs; chronic administration; neuroadaptation; antidepressants; antipsychotics; benzodiazepines; lithium; valproate; neuroplasticity; BDNF; dopamine; GABA.

Abstract

Chronic administration of psychotropic drugs produces therapeutic effects that often emerge together with time-dependent neurochemical and behavioral adaptations. These adaptations extend beyond acute receptor occupancy and include altered receptor density and coupling, neurotransmitter synthesis and release, intracellular signaling, gene transcription, neurotrophin regulation, synaptic remodeling, and circuit-level plasticity. The present evidence-based structured review synthesizes preclinical and clinical findings on long-term exposure to antidepressants, antipsychotics, benzodiazepines, lithium, and valproate. Particular attention is given to serotonin and norepinephrine adaptation, BDNF-TrkB and CREB signaling, dopamine D2 receptor regulation, GABA-A receptor plasticity, glutamatergic counter-regulation, GSK3-dependent pathways, histone deacetylase modulation, and the relationship of these changes to efficacy, tolerance, dependence, emotional blunting, tardive phenomena, cognition, and relapse vulnerability. The evidence indicates that chronic psychotropic treatment should be understood as a dynamic interaction between therapeutic neuroplasticity and homeostatic compensation. Antidepressants are associated with delayed neurotrophic and synaptic adaptations; chronic D2 antagonism can provoke striatal dopaminergic compensation in susceptible contexts; prolonged benzodiazepine exposure induces inhibitory synaptic remodeling that contributes to tolerance and withdrawal; and mood stabilizers exert broader intracellular and neuroprotective actions. Translation from animal models to humans remains incomplete, and many long-term effects are strongly influenced by dose, duration, diagnosis, age, co-medication, and withdrawal conditions. Rational psychopharmacology therefore requires periodic reassessment, gradual dose changes when clinically appropriate, and monitoring for class-specific neurobehavioral consequences.

References

1.D'Sa, C., & Duman, R. S. (2002). Antidepressants and neuroplasticity. Bipolar Disorders, 4(3), 183–194. https://doi.org/10.1034/j.1399-5618.2002.01203.x

2.Esalatmanesh, S., Kashani, L., & Akhondzadeh, S. (2023). Effects of antidepressant medication on brain-derived neurotrophic factor concentration and neuroplasticity in depression: A review of preclinical and clinical studies. Avicenna Journal of Medical Biotechnology, 15(3), 129–138. https://doi.org/10.18502/ajmb.v15i3.12921

3.Jawad, M. Y., Fatima, M., Hassan, U., Zaheer, Z., Ayyan, M., Ehsan, M., et al. (2023). Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature. Human Psychopharmacology: Clinical and Experimental, 38(4), e2871. https://doi.org/10.1002/hup.2871

4.Amato, D., Beasley, C. L., Hahn, M. K., & Vernon, A. C. (2017). Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neuroscience & Biobehavioral Reviews, 76(Pt B), 317–335. https://doi.org/10.1016/j.neubiorev.2016.10.004

5.Servonnet, A., & Samaha, A.-N. (2020). Antipsychotic-evoked dopamine supersensitivity. Neuropharmacology, 163, 107630. https://doi.org/10.1016/j.neuropharm.2019.05.007

6.Thompson, I. A., de Vries, E. F. J., & Sommer, I. E. C. (2020). Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment. Current Opinion in Psychiatry, 33(3), 200–205. https://doi.org/10.1097/YCO.0000000000000598

7.Piot, A., & Jovanovic, J. N. (2026). Synaptic correlates of benzodiazepine tolerance. Molecular Psychiatry, 31, 3775–3785. https://doi.org/10.1038/s41380-026-03512-8

8.Vinkers, C. H., & Olivier, B. (2012). Mechanisms underlying tolerance after long-term benzodiazepine use: A future for subtype-selective GABAA receptor modulators? Advances in Pharmacological Sciences, 2012, 416864. https://doi.org/10.1155/2012/416864

9.Ochoa, E. L. M. (2022). Lithium as a neuroprotective agent for bipolar disorder: An overview. Cellular and Molecular Neurobiology, 42(1), 85–97. https://doi.org/10.1007/s10571-021-01129-9

10.Abd-Eldayem, A. M. (2026). Valproic acid: Mechanistic insights into neuronal actions, epigenetic modulation, and clinical risk. Current Opinion in Pharmacology, 88, 102626. https://doi.org/10.1016/j.coph.2026.102626

11.The effect of antidepressant treatment on blood BDNF levels in depressed patients: A review and methodological recommendations for assessment of BDNF in blood. (2024). European Neuropsychopharmacology, 87, 35–55. https://doi.org/10.1016/j.euroneuro.2024.06.008

12.Silvestri, S., Seeman, M. V., Negrete, J. C., Houle, S., Shammi, C. M., Remington, G. J., et al. (2000). Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology, 152(2), 174–180. https://doi.org/10.1007/s002130000532

13.Silent action of dopamine receptor antagonist in synaptic remodelling: Molecular basis of tardive dyskinesia due to chronic antipsychotic exposure. (2026). Progress in Neuro-Psychopharmacology & Biological Psychiatry, 111846. https://doi.org/10.1016/j.pnpbp.2026.111846

14.Malhi, G. S., & Outhred, T. (2016). Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding. CNS Drugs, 30(10), 931–949. https://doi.org/10.1007/s40263-016-0380-1

15.Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: A systematic review. (2026). CNS Spectrums. https://doi.org/10.1017/S1092852926100996

Published

2026-09-25